AP NEWS

Know Labs Announces Laboratory Comparison Tests of Its UBAND Non-Invasive Blood Glucose Technology and Abbott Labs FreeStyle Libre

December 6, 2018

SEATTLE--(BUSINESS WIRE)--Dec 6, 2018--Know Labs, Inc. (OTCQB: KNWN), a provider of identification, authentication and diagnostic solutions, released today a video overview of comparison tests of the Company’s invention of its UBAND™ wearable to detect blood glucose non-invasively and Abbott Labs FreeStyle Libre. In the video Company CEO Phil Bosua discusses the breakthrough and highlights a comparison of the Know Labs UBAND Bio-RFID™ technology with an industry-leading continuous glucose monitor from Abbott Laboratories (NYSE: ABT).

The transcript of Phil Bosua’s narrative in the video states in part:

“We’ve spent the last couple of months updating all our test equipment and have now improved the accuracy of our Bio-RFID™ platform. This time we decided to benchmark multiple tests against the FDA approved FreeStyle Libre. It’s a really good device and I’m proud to say that we’re about 90% correlated to this CGM, which is even better than our previous Dexcom test.

“As we build this new revolutionary technology, that’s a nice shot in the arm. We look forward to sharing more positive results with you in the coming weeks.”

Link to video: https://youtu.be/JgV4pwRNUnU

Know Labs, Inc. is not affiliated with Abbott Laboratories or Dexcom. FreeStyle and Libre are registered trademarks of Abbott Laboratories.

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares currently trade under the stock symbol “KNWN.” The company’s technology directs structured light or radio waves through a substance or material to capture a unique molecular signature. The Company refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio-RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye. ChromaID and Bio-RFID scanner modules can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending, award-winning technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or large and expensive lab-based tests. For more information on Know Labs, visit the company’s website at www.knowlabs.co.

Safe Harbor Statement

This video at the link above and this release contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words may, would, will, expect, estimate, can, believe, potential and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181206005224/en/

CONTACT: Know Labs, Inc.

Jordyn Theisen

jordyn@knowlabs.co

Ph. 319-321-8470

KEYWORD: UNITED STATES NORTH AMERICA WASHINGTON

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES DIABETES

SOURCE: Know Labs, Inc.

Copyright Business Wire 2018.

PUB: 12/06/2018 09:00 AM/DISC: 12/06/2018 09:01 AM

http://www.businesswire.com/news/home/20181206005224/en

AP RADIO
Update hourly